Potential treatment for rare autoimmune disorder adapted from CAR-T therapy in study
Evidence from a small-scale clinical trial suggests that a variation of the blood cancer immunotherapy chimeric antigen receptor T-cell (CAR-T) could be adapted to treat myasthenia gravis (MG), an autoimmune disorder of the nervous system. Read More
Eli Lilly acquiring immune therapy developer Dice Therapeutics for $2.4B
Eli Lilly said this week it has inked an agreement to acquire Dice Therapeutics, a biopharma firm developing novel oral therapeutic candidates, for $2.4 billion in cash. Read More
Chikungunya vaccine candidate in clinical trial found generally safe and effective
A study of U.S. adults found that a vaccine candidate for chikungunya disease was generally safe and well tolerated. Read More
NIH funds work to develop protocol for re-administration of DMD gene therapies
The National Institutes of Health (NIH) is funding work that could show how the immune system reacts to muscle disease gene therapies and lead to a protocol for re-administration of the treatments. Read More
HIV nanoparticle vaccine induces strong T-cell responses in early-phase clinical trial
An HIV nanoparticle vaccine has induced strong T-cell responses in a first-in-human clinical trial, marking a step toward the development of a product that protects against the virus. Read More
Clinical trial begins for universal flu vaccine candidate
Researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAIDs) have developed an experimental universal influenza vaccine. Read More
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
Researchers have found a biomarker that provides an early indication of whether a patient is responding to chemo-immunotherapy. Read More
Novel glioblastoma treatment shows promising results
Toronto’s University Health Network (UHN) neurosurgeons have developed a novel glioblastoma therapy that combines the injection of an oncolytic virus directly into the tumor with intravenous immunotherapy. The results, published Monday in Nature Medicine, found that this combination therapy prolonged survival rates, providing clinical benefits to over half of the patients studied. Read More
Discovery of markers on long-lasting immune cells lights way to more durable vaccine responses
Researchers have identified surface markers on cells that continue producing antibodies for a long time, pointing to a way to improve the duration of response to vaccines. Read More
FDA approves first respiratory syncytial virus vaccine
The U.S. Food and Drug Administration (FDA) said Wednesday that it has approved the use of GlaxoSmithKline Biologicals’ Arexvy vaccine for respiratory syncytial virus (RSV). Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
